Company Legal Name
Latest Valuation
Founded Year
Headquarter
Freenome Holdings, Inc. develops advanced blood tests that analyze multiomic biomarkers to detect early-stage cancer signals, addressing the critical need for non-invasive cancer screening solutions. Founded in 2014 and headquartered in South San Francisco, the company leverages artificial intelligence and machine learning to identify patterns in circulating tumor DNA, proteins, and other biological markers present in blood samples. Freenome's platform aims to transform cancer detection by enabling earlier intervention when treatments are most effective. The company continues advancing its proprietary technology through clinical trials and partnerships, positioning itself at the forefront of liquid biopsy innovation in oncology diagnostics.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





